An observational study in Obstructive Sleep Apnea, sponsored by King's College London. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by King's College London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom — 9 open to participants now, 13 under way, none of them phase 3. Sleep Apnea, Obstructive · United Kingdom.
Among the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom, this one has the largest planned enrollment of the 28 observational ones that give a count, is one of 3 that started in 2026, is one of 28 observational ones, reaches primary completion later than 8 of the 12 other live ones, and was the 54th registered.
2,246 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →9 of the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom are open now. Recruiting first, the newest first:
Virginia Hawkins · Sites in United Kingdom
Ages 18+
Inspire Medical Systems, Inc. · Sites in United Kingdom, Austria, Belgium and 4 more countries
Ages 18+
University College, London · Sites in United Kingdom
Ages 18+ · Healthy volunteers
Children's Health Ireland · Sites in United Kingdom, Ireland
Ages 6 mo–16 yrs
Royal Free Hospital NHS Foundation Trust · Sites in United Kingdom
Ages 18–80
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 317 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 124 (39%) stop at 75 or younger; 53 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 2 · Phase 3 3 · Phase 4 1
First in 2005; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 105 across 668 observational studies indexed under Sleep Apnea, Obstructive.
Median enrollment 58 across the 26 interventional studies, 102 across the 28 observational. Of the 36 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 54 have an industry lead sponsor. The 10 most frequent:
King's College London is the lead sponsor of 524 studies on the registry; 130 are open to participants now.
King's College London has 5 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
2 of the studies in Sleep Apnea, Obstructive with a site in United Kingdom that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07497412King's College LondonThe Effect of Continuous Positive Airway Therapy on the Blood Pressure in Sleepy vs Non-sleepy Patients With Obstructive Sleep Apnea | 2026-11 |
| NCT06030349Children's Health IrelandClinical Outcomes From Treatment and Evaluation of Obstructive Sleep Apnoea in Children With Down Syndrome | 2027-11-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 54 studies in Sleep Apnea, Obstructive with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Obstructive sleep apnoea (OSA) is one of the most common noncommunicable types of disease, it affects about 1 billion people across the world. Left untreated, it causes apnoeas and hypopnoeas to fragment sleep, with frequent arousal from sleep and intermittent hypoxia associated with increased work of breathing. Frequently, it leads to excessive daytime sleepiness, as measured subjectively by the Epworth Sleepiness Scale, or, objectively, by the multiple sleep latency test (MSLT) or the maintenance of wakefulness test (MWT). OSA can lead to sustained high sympathetic tone at night, which in the long-term may impact on the cardiovascular risk.
The investigators hypothesised that any primary airway therapeutic effect on the cardiovascular system, as measured by the blood pressure, in patients with OSA will differ dependent on whether subjects are excessively sleepy, or remain so when treated.
Hypothesis
Introduction
Obstructive sleep apnoea (OSA) is one of the most common noncommunicable types of disease, it affects about 1 billion people across the world. Left untreated, it causes apnoeas and hypopnoeas to fragment sleep, with frequent arousal from sleep and intermittent hypoxia associated with increased work of breathing. Frequently, it leads to excessive daytime sleepiness, as measured subjectively by the Epworth Sleepiness Scale, or, objectively, by the multiple sleep latency test (MSLT) or the maintenance of wakefulness test (MWT). OSA can lead to sustained high sympathetic tone at night, which in the long-term may impact on the cardiovascular risk.
With optimised primary airway treatment, normal breathing at night resumes and patients experience a restoration of normal sleep architecture, with little or no further sleep fragmentation due to the underlying sleep disordered breathing. Daytime symptoms and quality of life typically improve with primary airway treatment, and long-term cardiovascular risks follows.
Data from the ANDANTE collaboration have recently shown that the effect of primary airway patency treatment in patients with obstructive sleep apnoea on the blood pressure control differs according to whether patients with OSA have normal blood pressure, controlled or uncontrolled hypertension. Furthermore, the high prevalence of OSA in the general population, frequently diagnosed randomly (e.g., screening prior to elective surgery) in otherwise asymptomatic patients raises the question whether symptoms, like sleepiness, that are associated with the syndrome predict outcomes on the cardiovascular system.
There are clinically relevant implications in who should and who should not be treated with OSA, particularly in the cohort of mild/moderate and asymptomatic patients with OSA, as recently discussed in the Baveno, and the modified Baveno classification. Furthermore, a proportion of patients with OSA who are adherent to primary airway therapy remain symptomatic, as measured by the Epworth Sleepiness Scale, a phenomenon that has been labelled residual excessive daytime sleepiness. The cardiovascular risk associated with patients who are excessively sleepy at baseline, and who remain so, is unclear.
The investigators hypothesised that any primary airway therapeutic effect on the cardiovascular system, as measured by the blood pressure, in patients with OSA will differ dependent on whether subjects are excessively sleepy, or remain so when treated.
Hypothesis
The investigators expected that the ANDANTE dataset could be used to address the clinically relevant question whether primary airway therapy of sleepy/non-sleepy patients with OSA provides benefits for associated long-term cardiovascular risks, as measured by the blood pressure values and 24h modulation (dipping vs non dipping). These questions form an essential aspect when discussing therapeutic options with patients in the sleep department, particularly in asymptomatic patients with mild/moderate OSA.
Methods The purpose of this study was to retrospectively analyse the ANDANTE database using the individual patient data (IPD) from the recently published meta-analysis using the ANDANTE database, details of which have been published elsewhere (Pengo M et al, European Respiratory Journal 2025). The study was approved by the King's College London ethics committee (17/12/2025; MRA-25/26-53856) and, following peer-review, by the scientific committee of the ANDANTE collaboration (Application date: 17/12/2024).
The investigators sought to investigate the dataset by stratifying patients based on excessive sleepiness, defined as an Epworth Sleepiness Scale (ESS) score greater than 10 points (a) at baseline, and (b) at follow up.
Statistical Analysis Plan Data management
This study will retrospectively analyse the ANDANTE database using individual patient data (IPD) from the previously published meta-analysis (Pengo M et al, European Respiratory Journal 2025). As a first step, we will stratify patients based on the Epworth Sleepiness Scale (ESS) both at baseline and at follow-up, considering a threshold of 10 points. From this stratification, we will create multiple study groups from which we will evaluate our primary and secondary outcomes:
Baseline non-sleepy patients (ESS ≤10).
Primary Outcome The effect of baseline sleepiness classification (ESS > or ≤ 10) on the blood pressure response to CPAP treatment in patients with OSA (groups 1 vs 2).
Secondary Outcomes I) The effect of residual vs improving sleepiness on the blood pressure response to CPAP treatment in patients with OSA (groups a vs b).
II) Difference in adherence levels (measured by follow-up average daily use) between sleepy and non-sleepy patients at baseline and follow-up (groups 1 vs 2, and a vs b).
III) Effect of adherence in treatment responses (groups 1 vs 2, and a vs b).
Analytical Approach
1. Linear mixed models, predicting follow-up blood pressure measurements (dependent variables) by the above-described groups (ESS classifications), considering baseline blood pressure measurements and CPAP adherence as covariate, fixed effects.
Statistical Reporting
Differences will be described as 95% confidence intervals and significance defined as p\<0.05.
Adult patients with OSA who were randomised in an interventional trial to treat the condition using primary airway therapy (e.g., CPAP) in a randomised controlled trial (included in the ANDANTE database, Pengo M, Eur Resp J 2025)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with obstructive sleep apnea who are excessively sleepy, as measured by the Epworth Sleepiness Scale (ESS) \> 10 points
Device: Primary airway therapy (e.g., CPAP) · Other: Control arm
Patients with obstructive sleep apnea who are not excessively sleepy, as measured by the Epworth Sleepiness Scale (ESS) \<= 10 points
Device: Primary airway therapy (e.g., CPAP) · Other: Control arm
Treatment to restore upper airway patency in the asleep patient with OSA (e.g., CPAP)
Control arm included in the randomised controlled trials of the ANDANTE database
Office blood pressure
Office blood pressure measurements (systolic, diastolic in mmHg)
Time frame: through study completion, an average of 3months
24 hours blood pressure
average systolic and diastolic blood pressure over 24 hours (mmHg)
Time frame: through study completion, an average of 3months
Nocturnal blood pressure dipping pattern
Drop in nocturnal blood pressure (yes / no; \>10% compared to daytime BP)
Time frame: through study completion, an average of 3months
Change in Epworth Sleepiness Scale associated with blood pressure changes (office, systolic / diastolic); minimal score 0, maximal score 24 points; higher scores indicate more severe sleepiness
Change in ESS (points out of 24) from baseline to follow up and associated change in blood pressure (mmHg)
Time frame: through study completion, an average of 3months
Adherence to treatment
Usage of CPAP therapy (hours per night)
Time frame: through study completion, an average of 3months
Plan to share: No — The ANDANTE database is an established open access registry in Milan / Italy and researchers can apply with the University of Milan-Bocca to access these data.
Started Jan 2026 (actual). Primary completion is estimated for Nov 2026, 10 months after the start.
Of 258 non-industry observational studies under Sleep Apnea, Obstructive, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 63. This study's planned 10 months is below that.
Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 14 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.